英菲格拉替尼(Infigratinib)各版本价格一览表

Infigratinib is a targeted treatment drug for FGFR2 gene abnormalities. This article will detail the prices, medication guidelines and precautions for special groups of each version to help patients better understand this drug.

Price list of various versions of Infigratinib

The original drug of Infigratinib is more expensive, while generic drugs provide patients with a more economical choice. At present, infigratinib has not yet been officially launched in mainland China.

Specifications and Prices

The generic version of Infigratinib produced by Lucius Pharmaceuticals in Laos has a specification of 100mg*21 capsules/box and a price of approximately US$471. Patients should pay attention to the reliability of the source of the drug when choosing to avoid buying fake and shoddy drugs.

Are generic drugs effective?

Generic drugs are consistent with the original drugs in terms of active ingredients, dosage form, dosage and route of administration, so they have similar efficacy. Many international authoritative organizations have strict supervision on the quality and effectiveness of generic drugs. For patients with limited financial conditions, generic drugs are an option worth considering.

Infigratinib Medication Guide

The correct use of Infigratinib is crucial to the therapeutic effect. The following are specific medication recommendations and precautions.

Recommended dose

The standard dose is 125 mg (100 mg + 25 mg capsule), once a day, taken for 21 consecutive days and then stopped for 7 days, with a cycle of 28 days. It needs to be taken on an empty stomach, 1 hour before a meal or 2 hours after a meal is the best time.

Handling of missed doses or vomiting

If you miss a dose for more than 4 hours or vomit, there is no need to take another dose. Just continue with the next dose as originally planned. Avoid adjusting the dose at will, so as not to affect the efficacy or increase the risk of side effects.

Drug interactions

Avoid combined use with strong CYP3A inhibitors (such as itraconazole) or inducers (such as rifampicin). Gastric acid inhibitors may affect drug absorption. If combined use is required, it must be taken at a certain interval.

There may be differences in medication regimens for different groups of people, and special patients need to pay special attention to medication safety.

Special medication groups for Infigratinib

Due to special physiological or pathological conditions, some patient groups need to adjust the dosage or strengthen monitoring during medication.

Patients with hepatic and renal insufficiency

The recommended dose for patients with mild to moderate hepatic impairment is 100 mg (mild) or 75 mg (moderate). For patients with mild to moderate renal impairment, the dose is adjusted to 100 mg. Patients with severe hepatic and renal insufficiency need to carefully evaluate the medication regimen.

Pregnant and lactating women

This drug may cause harm to the fetus and is contraindicated by pregnant women. Women of childbearing age need to take effective contraceptive measures during treatment and within 1 month after stopping the drug. Women who are breastfeeding should suspend breastfeeding.

Elderly patients

The drug safety of elderly patients is not significantly different from that of younger people, but the dosage still needs to be adjusted according to individual conditions and adverse reactions must be closely monitored.

Infigratinib may cause side effects such as nail toxicity, dry mouth, and fatigue. Patients need to be reviewed regularly during the medication and seek medical attention promptly if they feel unwell. The doctor will adjust the treatment plan according to the situation.